AnaptysBio, Inc.
anaptysbio.comWhat Do They Do?
Licenses antibody programs to pharmaceutical partners, including Jemperli to GSK and imsidolimab to Vanda.
10-K for FY2025, filed Mar 3, 2026
How Do They Make Money?
Anaptys receives royalties and milestone payments under its GSK collaboration and license and transition-services revenue from Vanda. Vanda paid an upfront license fee and drug-supply amount and may pay royalties on net sales and milestone payments when specified events occur.
10-K for FY2025, filed Mar 3, 2026
-
10-K for FY2025, filed Mar 3, 2026
FY2025 revenue by reportable segment ↗
$234.6M
-
10-K for FY2025, filed Mar 3, 2026
$234.6M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Biopharma
|
0.0% |
Biopharma, FY2025
$0 Sources
|
|
|
Royalty Management
Licensed
10-K for FY2025, filed Mar 3, 2026 |
100% |
Royalty Management, FY2025
$234.6M Sources
|
Licensed |
Who Are Their Customers?
GSK and Vanda are pharmaceutical partners that license antibody programs directly from Anaptys; Vanda holds an exclusive global license for imsidolimab.
10-K for FY2025, filed Mar 3, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q1 FY2026, filed May 12, 2026
−$52.9MView ↗
- ▲ +34% (Loss)
- vs −$39.3M in Q1 FY2025
10-Q for Q1 FY2026, filed May 12, 2026
Open tableView ↗
-
May 12, 2026
Anaptys gave a future Jemperli royalty outlook
It expects annualized royalties above $390 million as early as 2029, based on GSK peak sales guidance above $2.7 billion.
Sources
8-K, filed May 12, 2026
Anaptys continues to expect to achieve >$390 million in annualized Jemperli royalties payable to Anaptys as early as 2029 at GSK’s peak…View ↗
-
May 11, 2026
Anaptys appointed a new CFO
Sources
8-K, filed May 11, 2026
On May 11, 2026, AnaptysBio, Inc. (the “Company”) announced that its Board of Directors (the “Board”) appointed Christopher M. Murphy as…View ↗
-
Apr 20, 2026
Anaptys completed the First Tracks spin-off
Anaptys now exclusively manages the Jemperli and imsidolimab financial collaborations.
Sources
8-K, filed Apr 20, 2026
SAN DIEGO, CA — April 20, 2026 — AnaptysBio, Inc. (Nasdaq: ANAB), a royalty management company, today announced the completion of its…View ↗
Growing. Revenue grew 3.7x in 4 years, from $63.2M in FY2021 to $234.6M in FY2025, about 39% a year.
Imsidolimab licensing
Imsidolimab moved from a program Anaptys planned to out-license to one licensed exclusively to Vanda worldwide for development and commercialization.
10-K for FY2022, filed Mar 1, 2023 10-K for FY2025, filed Mar 3, 2026We announced in August 2022 that we intend to complete execution of our Phase 3 program in GPP and out-license imsidolimab prior to…View ↗
On January 31, 2025, we entered into an Exclusive License Agreement (the “Vanda License Agreement”) with Vanda pursuant to which we granted…View ↗
Who Do They Compete With?
Competes with Gilead, Seismic Therapeutics, Abbvie, Roche, Regeneron, BMS, Eli Lilly, Pfizer, Forte Bioscience, Novartis, Teva, Biogen, Dianthus Therapeutics, and Amgen
10-K for FY2025, filed Mar 3, 2026For rosnilimab, our competitors include non-depleting PD-1 agonist antibodies GS-0151, (Gilead) in Phase 1b development for the treatment…View ↗
Loading...
